Green, M. M. B., Horwitz, M. E., Kang, Y., Chao, N. J., Long, G. D., Rizzieri, D., … Stuart, R. (2015). Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. In Biology of Blood and Marrow Transplantation (Vol. 21, pp. S31–S32). Elsevier BV. https://doi.org/10.1016/j.bbmt.2014.11.024

Green, Michael M. B., Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” In Biology of Blood and Marrow Transplantation, 21:S31–32. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.024.

Green MMB, Horwitz ME, Kang Y, Chao NJ, Long GD, Rizzieri D, et al. Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S31–2.

Green, Michael M. B., et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” Biology of Blood and Marrow Transplantation, vol. 21, no. 2, Elsevier BV, 2015, pp. S31–32. Crossref, doi:10.1016/j.bbmt.2014.11.024.

Green MMB, Horwitz ME, Kang Y, Chao NJ, Long GD, Rizzieri D, Gasparetto C, Sung AD, Sarantopoulos S, Li Z, Corbet K, Riggan-Stuelke E, Sullivan K, Wilson B, Chhabra S, Costa LV, Mims A, Stuart R. Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial. Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S31–S32.